Desvenlafaxine: SNRI as active major metabolite of venlafaxine
Desvenlafaxine (chemically O-desmethylvenlafaxine) is a selective serotonin-noradrenaline reuptake inhibitor (SNRI) that is pharmacologically the active major metabolite of venlafaxine. In the United States, desvenlafaxine was approved in 2008 under the trade name Pristiq; in Europe, the EMA granted approval in 2010 for major depression, but the manufacturer withdrew the product from the European market in 2018.
In Germany, desvenlafaxine is therefore not currently available through regular channels but can be obtained on a case-by-case basis through international pharmacies. In countries such as the USA, Canada, Australia, and some Latin American countries, it remains established. The active ingredient has a fixed place in the treatment of major depression in adults, particularly in patients who respond well to venlafaxine but show highly fluctuating levels due to CYP2D6 polymorphism.
Mechanism of action
Desvenlafaxine inhibits the reuptake of serotonin and noradrenaline at presynaptic nerve terminals, with somewhat lower affinity for the serotonin transporter (SERT) than for the noradrenaline transporter (NET) compared to venlafaxine. This dual action increases the concentration of both neurotransmitters in the synaptic cleft and is the basis of the antidepressant effect.
Unlike venlafaxine, which must be metabolized in the liver by CYP2D6 to desvenlafaxine, desvenlafaxine itself is the active form. Patients who are poor or ultra-rapid metabolizers for CYP2D6 (approximately 7 percent of the European population) often show inconsistent response to venlafaxine but benefit from more stable levels with desvenlafaxine. This makes the active ingredient particularly interesting for patients who have been pharmacogenetically characterized.
Pharmacokinetically, oral bioavailability is approximately 80 percent, half-life is 11 hours, and elimination is renal after conjugation. The pharmacokinetics are linear and predictable, which facilitates dose titration.
Indications
- Major depression in adults: Standard SNRI indication
- Hot flushes in menopause: Off-label; studied in some trials in the USA
- Generalized anxiety disorder: Off-label; displaced by venlafaxine and duloxetine
- Chronic pain syndromes: Off-label discussion; limited data
Dosage and administration
Standard dose: 50 mg once daily, at approximately the same time each day. Higher doses (100 mg, 150 mg, 200 mg) show no clearly superior effect in studies, but more side effects.
Renal impairment: Reduce dose or avoid use in moderate to severe functional impairment, as desvenlafaxine is eliminated predominantly renally. Hepatic impairment: Dose adjustment required in moderate to severe insufficiency.
Elderly patients: Standard dose 50 mg, cautious increase due to increased risk of hyponatremia.
Treatment discontinuation: Taper slowly over at least 4 weeks to avoid discontinuation symptoms.
Side effects
Very common: Nausea (especially in the first few weeks), dry mouth, dizziness, sleep disturbances, sweating, constipation, sexual dysfunction (reduced libido, erectile dysfunction, delayed orgasm), fatigue.
Common: Headaches, tremor, decreased appetite, weight loss, dose-dependent blood pressure increase, tachycardia, mydriasis.
Serious, rare: Suicidal thoughts especially in the first few weeks in younger patients, hyponatremia (particularly in elderly, often as SIADH), serotonin syndrome in combination with other serotonergic agents, seizures, bleeding tendency (particularly gastrointestinal when combined with NSAIDs or anticoagulants), QT prolongation, narrow-angle glaucoma triggering.
Important: Patients and relatives should watch for mood deterioration, suicidal thoughts, or unusual behavioral changes in the first few weeks and should seek medical help if in doubt.
Drug interactions
- MAO inhibitors (tranylcypromine, moclobemide, linezolid): Life-threatening serotonin syndrome, combination contraindicated; at least 14 days washout
- Other serotonergic agents (SSRIs, triptans, tramadol, lithium, St. John's wort): Serotonin syndrome risk, caution and patient information needed
- NSAIDs and anticoagulants: Increased bleeding risk, especially gastrointestinal
- QT-prolonging agents: Additive QT prolongation
- Alcohol: Additive CNS effects
- Tamoxifen: Possible interaction via CYP2D6, but less relevant than with venlafaxine
Special notes
Pregnancy and breastfeeding: Desvenlafaxine should be used in pregnancy only under strict indication. SNRIs in the third trimester can cause adjustment disorders, respiratory depression, and persistent pulmonary hypertension in the newborn. Use is possible during breastfeeding; monitor the infant.
Blood pressure monitoring: Desvenlafaxine may dose-dependently increase blood pressure. Measure blood pressure before therapy and during treatment; if hypertension develops, consider therapy adjustment.
Suicidality: As with all antidepressants, suicidal thoughts are possible in the first few weeks, especially in younger patients. Patient education and close monitoring are important.
Discontinuation symptoms: Abrupt discontinuation can cause dizziness, nausea, headaches, irritability, sleep disturbances, visual disturbances, and electric shock sensations. Gradual dose reduction over 4 weeks or longer is standard.
You might also be interested in
- Venlafaxine, the predecessor antidepressant
- Duloxetine, another SNRI
- Sertraline, classic SSRI
- Escitalopram, another SSRI
- Mirtazapine, alternative antidepressant with different mechanism of action
Frequently asked questions
What is the advantage of desvenlafaxine over venlafaxine?
Desvenlafaxine is the active form that does not need to be formed first by CYP2D6 in the liver. In patients with unusual CYP2D6 genotype (poor or ultra-rapid metabolizer), levels are more stable and predictable with desvenlafaxine. In studies, the efficacy of both substances was comparable, and the side effect profile was similar.
When does desvenlafaxine work for depression?
First improvements are noticeable after 2 to 4 weeks; full response develops over 6 to 8 weeks. If response is insufficient after 8 weeks, discuss with your physician whether dose increase, switching, or combination therapy makes sense.
Why is desvenlafaxine not regularly available in Germany?
Pfizer withdrew desvenlafaxine (Pristiq) from the European market in 2018, primarily for economic reasons, as venlafaxine generics are inexpensively available and the added benefit for most patients is limited. It remains on the market in the USA. It can be imported on a case-by-case basis through international pharmacies.
What to do if discontinuation symptoms occur?
If you experience dizziness, nausea, headaches, or electric shock sensations after stopping, the reduction should proceed more slowly, possibly with resumption of the previous dose and slower tapering. Gradual reduction over 4 to 8 weeks or longer significantly reduces the risk.
Sources
- FDA product information Pristiq (desvenlafaxine)
- AWMF S3 guideline unipolar depression
- Gelbe Liste, desvenlafaxine active ingredient profile
- BfArM, Federal Institute for Drugs and Medical Devices
Legal notice and disclaimer
The information provided on this page is for general information purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It does not replace the advice of a licensed physician or pharmacist. Medicines should only be taken as prescribed by a physician or dispensed as pharmacy-required medication. All information is based on expert information published at the time of preparation and recognized scientific sources; the current product information from the manufacturer is always authoritative. Sanoliste assumes no liability for completeness, timeliness, or accuracy of the information presented. In case of medical emergency, call emergency number 112.